Pipeline

September 16, 2019

Company	Drug/Device	Medical Condition	Status
Selvita	SEL120	acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS)	Phase 1b trial initiated enrolling subjects at sites across the U.S.
VBI Vaccines Inc.	VBI-1901 in combination with GlaxoSmithKline’s proprietary AS01B adjuvant system	recurrent glioblastoma (GBM)	Phase 2a trial initiated enrolling 20 subjects with first-recurrent GBM only
Recardio, Inc.	dutogliptin in combination with filgrastim	post-myocardial infarction	Phase 2 trial initiated enrolling 140 subjects at specialized cardiology centers located throughout Europe and the U.S.
Alector, Inc.	AL001	frontotemporal dementia (FTD) with specific genetic mutations, including the granulin gene (FTD-GRN)	Phase 2 trial initiated enrolling 32 subjects with FTD-GRN and an additional cohort of FTD subjects with a C9orf72 mutation (FTD-C9orf72)
Biohaven Pharma Holding Company Ltd.	vazegepant	acute treatment of migraine	Phase 2/3 trial initiated
Lipidor AB	Calcipotriol/AKVANO 50 µg/g cutaneous solution (AKP01)	mild to moderate psoriasis	Phase 3 study initiated enrolling 277 subjects at 14 clinics across India
Functional Neuromodulation	fornix (DBS-f)	mild Alzheimer's Disease	Phase 3 study initiated enrolling 210 people 65 years or older with mild Alzheimer's disease at 14 study sites in the U.S., Canada and Germany
EMD Serono	evobrutinib	relapsing multiple sclerosis (RMS)	Two phase 3 studies initiated enrolling 1,900 adult subjects
Nevakar Inc.	NVK-002	slow the progression of myopia in children	Phase 3 study initiated enrolling 576 child subjects aged 3 to 17 years in Asia, the U.S. and Europe
Netech	Delta 3300	arrhythmia	510(k) approval granted by the FDA
Merck KGaA	tepotinib	metastatic non-small cell lung cancer (NSCLC)	Breakthrough Therapy Designation granted by the FDA
Horizon Therapeutics plc	teprotumumab	active thyroid eye disease (TED)	Priority Review granted by the FDA
Almirall LLC	Aczone 7.5% topical gel	acne vulgaris	Approval granted by the FDA
Jenkins Eye Care	AcrySof IQ PanOptix Trifocal Intraocular Lens (IOL)	cataract	Approval granted by the FDA
Axonics Modulation Technologies, Inc.	implantable rechargeable sacral neuromodulation (“SNM”) device	urinary and bowel dysfunction	Approval granted by the FDA
Boehringer Ingelheim Pharmaceuticals	Ofev (nintedanib) capsules	interstitial lung disease associated with systemic sclerosis or scleroderma (SSc-ILD)	Approval granted by the FDA